Gelonghui February 3rd 丨Eling Pharmaceutical (002603.SZ) announced that on February 3, 2023, the company held the 27th meeting of the 7th board of directors and the 17th meeting of the 7th board of supervisors to review and pass the “Proposal on Using Temporarily Idle Own Funds to Purchase Short-Term Wealth Management Products” respectively. It was agreed that under the circumstances of guaranteeing the company's daily operating capital requirements and effectively controlling investment risks, the company could use part of its temporarily idle own funds to purchase medium- to low-risk, high-security, and high-liquidity short-term wealth management products, with an amount not exceeding RMB 3 billion (including the 24th session of the company's 7th board of directors) The conference resolution reviewed and passed RMB 1.5 billion). The amount purchased for wealth management products can be used on a rolling basis within 12 months from the date of review and approval by the Board of Directors.